ImmusanT, Inc., a Cambridge, Mass.-based clinical stage company that is leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to translate and deliver first-in-class peptide-based immune therapies to people living with autoimmune diseases, received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding the best type 1 diabetes (T1D) commercial opportunities.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate the translation of insights and clinical experience gained from its celiac disease program to the development of a novel vaccine candidate for T1D.
Led by Leslie Williams, Chief Executive Officer, ImmusanT is developing a new class of therapeutic vaccines for people living with autoimmune diseases. Its lead candidate is Nexvax2®, a peptide-based therapeutic vaccine, which has demonstrated safety and relevant bioactivity in multiple Phase 1 studies for celiac disease, an-HLA associated disease with many similarities to T1D.